ClaudiaLOrdonezMD
Pediatric Pulmonology • Boston, MAPediatric Asthma Pulmonology
Clinical Instructor in Pediatrics, Boston Children's Hospital
Are you Dr. Ordonez?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-1900Fax+1 617-730-0084
Summary
- Dr. Claudia Ordonez, MD is a pediatric pulmonologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is affiliated with Boston Children's Hospital and is a Clinical Instructor in Pediatrics at Boston Children's Hospital.
Education & Training
University of California (San Francisco)Fellowship, Pediatric Pulmonology, 1995 - 1998
Children's Hospital-OaklandResidency, Pediatrics, 1991 - 1994- University of California San Francisco School of MedicineClass of 1991
Certifications & Licensure
MA State Medical License 1998 - 2026
Publications & Presentations
PubMed
- 111 citationsSweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial dataFrank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne Stone, Qunming Dong
Journal of Cystic Fibrosis. 2014-03-01 - 41 citationsOptimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.Steven M. Rowe, Bo Liu, Aubrey E. Hill, Heather Hathorne, Morty Cohen
Plos One. 2013-07-26 - 366 citationsEfficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D MutationJane C. Davies, Claire E. Wainwright, Gerard J. Canny, Mark A. Chilvers, Michelle S. Howenstine
American Journal of Respiratory and Critical Care Medicine. 2013-06-01
Press Mentions
- Keros Therapeutics Appoints Simon Cooper, M.B.B.S. As Chief Medical OfficerAugust 2nd, 2021
Grant Support
- Phase 2 Study Of VX-770 In Cystic Fibrosis Subjectswith G551DFood And Drug Administration2007
- Formula Forified W/ Docosahexaenoic Acid (DHA) In Infants W/ Cystic FibrosisNational Center For Research Resources2006
- Assessment Of Induced Sputum As A Tool To Evaluate Anti-Inflammatory AgentsNational Center For Research Resources2006
- P Aeruginosa Virulence In Cystic Fibrosis Lung DiseaseNational Heart, Lung, And Blood Institute2005–2006
- Use Of Sputum IND To Study Infection &Inflam In Child W/Cf PHS I&IiNational Center For Research Resources2005
- Tissue Bank For Pulmonary DiseasesNational Center For Research Resources2004–2005
- P. Aeruginosa Virulence In Cystic Fibrosis Lung DiseaseNational Heart, Lung, And Blood Institute2004
- Use Of Sputum Ind. To Study Infection &Inflam. In Child. W/C.F. PHS I&IiNational Center For Research Resources2004
- Study Of Airway Inflammation In Subjects With Cystic FibrosisNational Center For Research Resources2004
- Phase I Trial Comparing Two Delivery Methods And Doses Of Tobi In CF PatientsNational Center For Research Resources2004
- Cystic Fibrosis Once Daily Aminoglycoside Clinical Trial (CFODACT)National Center For Research Resources2004
- Free Elastase In BAL Fluid In Cystic Fibrosis PatientsNational Center For Research Resources2000–2002
- Airway Inflammation In Cystic FibrosisNational Center For Research Resources2000–2002
